Abstract:Objective To describe the clinical features of pediatric chronic granulomatous disease (CGD) and incidence of infection after treatment program (combine rhIFN-γ and TMP-SMX). Methods The follow-up study of clinical features, including the site of infection, the pathogen of infection, noninfectious inflammatory response and drug treatment, etc., was performed in CGD patients diagnosed in Children′s Hospital of Fudan University from January 2004 to December 2011. The incidence of infection calculated as per patient-year was compared between patients who received combination treatment program or separated TMP-SMX treatment. The clinical efficacy and safety of rhIFN-γ treatment were analyzed. Results A total of 29 cases were recruited into the study. The mean age of onset and diagnosis was 2.5 months and 2.4 years respectively. Mean duration of per follow-up patient was 2.9 years. ① The incidence of all infections, severe infections and non-severe infections was 1.8, 0.48 and 0.80 per patient-year. Lung infection and lymphadenitis were the most frequent manifestations both prior to diagnosis (49 and 26) and during follow-up (26 and 37). Mycobacteria species was the leading cause of infection (34/61) and death (3/4) in our cohort. ② Combined treatment program was used in 21 cases while separated TMP-SMX treatment was performed in 8 cases because of drug adverse reaction or self-withdrawal. After combined treatment, the incidence of total and severe infection was significantly lower than that prior to treatment(total infection: 1.986 vs 1.098, P=0.002; severe infection:1.290 vs 0.452, P=0.001), the most remarkable to the lung (0.758 vs 0.275, P=0.004), the incidence of infection did not significantly differ from separated TMP-SMX treatment. The incidence of total and non-severe infection in combined treatment program was significant lower than that in separated TMP-SMX treatment (total infection: 1.098 vs 1.823, P=0.015; non-serious infection: 0.646 vs 1.248, P=0.047), serious infection had no significant difference (0.452 vs 0.576, P=0.254). ③ 14/29(48.3%)cases reported an adverse event after the use of rhIFN-γ, the commonest was fever (12/29). There was no life-threatening rhIFN-γ-related adverse events. Conclusions Combined treatment program significantly reduced the incidence of infection. The use of rhIFN-γ in patients with CGD appeared to be effective and safe. Mycobacteria species was the first cause of infection and death in our cohort.

High Levels of IL-18 and IFN-γ in Chronically Inflamed Tissue in Chronic Granulomatous Disease

Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD)

Inflammatory Complications in Chronic Granulomatous Disease

Hyperinflammation of Chronic Granulomatous Disease is Abolished by NOX2 Reconstitution in Macrophages and Dendritic Cells

Olfm4 deletion enhances defense against Staphylococcus aureus in chronic granulomatous disease.

TNFα: TNFR1 signaling inhibits maturation and maintains the pro-inflammatory programming of monocyte-derived macrophages in murine chronic granulomatous disease

Genetic Characteristics, Infectious, and Noninfectious Manifestations of 32 Patients with Chronic Granulomatous Disease

Clinical presentation, diagnosis, and treatment of chronic granulomatous disease

NADPH Oxidase Limits Collaborative Pattern-Recognition Receptor Signaling to Regulate Neutrophil Cytokine Production in Response to Fungal Pathogen-Associated Molecular Patterns.

Bacillus Calmette-Guerin Infection in NADPH Oxidase Deficiency: Defective Mycobacterial Sequestration and Granuloma Formation.

Geographic Variability and Pathogen-Specific Considerations in the Diagnosis and Management of Chronic Granulomatous Disease

Molecular quality control machinery contributes to the leukocyte NADPH oxidase deficiency in chronic granulomatous disease.

Reactive Oxygen Species Produced by the NADPH Oxidase 2 Complex in Monocytes Protect Mice from Bacterial Infections.

Phenomic Analysis of Chronic Granulomatous Disease Reveals More Severe Integumentary Infections in X-Linked Compared With Autosomal Recessive Chronic Granulomatous Disease

Nadph Oxidase Limits Innate Immune Responses In The Lungs In Mice

Genotype-Phenotype Correlations in Chronic Granulomatous Disease: Insights From a Large National Cohort

Clinical Features of Chronic Granulomatous Disease: Analysis of 27 Cases

NOX2 deficiency enhances priming and activation of the NLRP3 inflammasome

In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease.

Moderate-and long-term follow up of chronic granulomatous disease and efficacy of preventive drugs

Macrophage Activation Syndrome as a Complication of Chronic Granulomatous Disease: A Case Report